A Study of CBP-1018 in Patients With Advanced Solid Tumors

Solid Tumor Clinical Trial

Official title:

An Open-Label, Non-randomized, Multi-center Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1018 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04928612
• Other study ID #: CBP-1018-101
• Status: Recruiting
• Phase: Phase 1
• Start date: November 4, 2021
• Est. completion date: October 2024

Study information

• Verified date: March 2023
• Source: Coherent Biopharma (Suzhou) Co., Ltd.
• Contact: Jiangang Yu, Ph D
• Phone: 0512-85550899
• Email: jiangang.yu[@]coherentbio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, non-randomized, multi-center, phase I study of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors. This study will be conducted in 2 parts: Part A (Dose Escalation) and Part B (Dose Expansion). Both parts include screening period, treatment period, end of treatment (EOT)/withdrawal, safety follow-up (SFU) and long-term-follow-up (LTFU). CBP-1018 will be administrated on eligible subjects until disease progression, unacceptable toxicity, withdrawal of consent or Sponsor's decision to stop the study, etc.

Description:

Part A (Dose Escalation) is to evaluate the safety, tolerability, PK and preliminary efficacy of CBP-1018 and determine the MTD and RP2D of CBP-1018 administrated iv Q2W (4 weeks/cycle), utilizing accelerated titration at lower doses (0.03 mg/kg and 0.06 mg/kg) and an i3+3 design at following doses (0.08 mg/kg,0.10 mg/kg,0.12 mg/kg and 0.14mg/kg, etc.), respectively. The DLT evaluation period will be 28 days from the first dose of CBP-1018. Up to 2 subjects will be allowed under DLT evaluation period at the same time. The interval between the first treatment of CBP-1018 to the 2 subjects under DLT evaluation period at the same time, is at least 1 week. Safety monitoring committee (SMC), comprised of Investigators and sponsor's medical personnel, etc., will be responsible for safety monitoring, dose escalation safety review and justification, MTD/RP2D determination, and other critical study decisions. A higher dose level may be added on the decision of SMC, if MTD is not observed at 0.14mg/kg. Intermediate dose levels among planned dose levels may also be added by SMC for further exploration. RP2D may be the same dose level as MTD or lower than it. Up to 10 additional subjects will be enrolled in one or more dose levels that have been shown to be safe and tolerable to better estimate the RP2D and better characterize the safety, efficacy, and pharmacodynamics for CBP-1018. Different schedules (QW or Q3W, for example) may be explored in Part A, according to emerging clinical and PK data, either.

Part B (Dose Expansion) is to further evaluate the efficacy and safety profile of CBP-1018 in 4 tumor-specific cohorts, with a Simon's two-stage design in each cohort:

• Cohort 1 (Metastatic castration resistant prostate cancer, mCRPC): subjects with mCRPC have documented failure of prior standard of care (SoC), such as new hormone therapy (Enzalutamide, apalutamide, etc.), Abiraterone and chemotherapy (Docetaxel, Cabazitaxel, etc.).

• Cohort 2 (Advanced renal cell cancer, RCC): subjects with advanced RCC have documented failure of prior SoC, such as immunotherapy (PD-1/L1 antibody) combined with anti-angiogenic therapy, targeted therapy (VEGF or mTOR inhibitor, etc.).

• Cohort 3 (Advanced lung squamous cell cancer, LSCC): subjects with advanced LSCC have documented failure of prior SoC, such as immunotherapy (PD-1/L1 antibody) combined with chemotherapy (platinum-based regimen)，chemotherapy (Taxane, Gemcitabine, etc.).

• Cohort 4 (Other advanced solid tumors): subjects with other advanced solid tumors have documented failure of prior SoC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: October 2024
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provision of informed consent (ICF) prior to any study-specific procedures.

• Men or women = 18 years old when signed ICF.

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

• Life expectancy of = 3 months, in the opinion of the Investigator.

• Pathologically documented, advanced solid tumor including metastatic castration resistant prostate cancer (mCRPC), advanced renal cell cancer (RCC), advanced lung squamous cell cancer (LSCC), etc.

• Subjects must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the Investigator, would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy.

• At least one non-irradiated measurable lesion per RECIST 1.1 or bone lesion per PCWG3 (only for mCRPC), optional for low dose level (= 0.08 mg/kg) of Part A.

• Available archived or fresh tumor tissue samples, optional for low dose level (= 0.08 mg/kg) of Part A.

• Adequate bone marrow and organ function, defined as:

• Absolute neutrophil count (ANC) = 1.5 × 109/L, not requiring growth factor support for at least 28 days prior to the first dose of CBP-1018.

• Hemoglobin (Hb) = 100 g/L, not requiring transfusion support for at least 14 days or growth factor support for at least 28 days prior to the first dose of CBP-1018.

• Platelet count = 100 × 109/L, not requiring transfusion support for at least 7 days prior to the first dose of CBP-1018.

• Total bilirubin (TBIL) = 1.5 × ULN, alkaline phosphatase (ALP) = 1.5 × ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3.0× ULN if no demonstrable liver metastases.

• TBIL= 1.5 × ULN, ALT and AST = 5.0 × ULN in the presence of liver metastases.

• TBIL < 2.0 × ULN for subjects with documented Gilbert's syndrome or < 3.0 × ULN for subjects for whom the indirect bilirubin level suggests an extrahepatic source of elevation.

• Creatinine = 1.0 × ULN, or creatinine clearance = 50 mL/min as calculated using Cockcroft-Gault formula.

• International Normalized Ratio (INR) = 1.5 × ULN (within the therapeutic range for subjects receiving anticoagulation therapeutic) and activated partial thromboplastin time (APTT) = 1.5 × ULN.

• LVEF = 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA).

• Female subjects of childbearing/reproductive potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of CBP-1018. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

• Male subjects of fathering potential and subjects of childbearing/reproductive potential must agree to use highly effective methods of contraception (see Appendix 4) throughout the study and for at least 30 days after the last dose of CBP-1018.

Exclusion Criteria:

• Known prior or suspected hypersensitivity to study drugs or any component in their formulations.

• Concurrent malignancy within 5 years prior to the first dose of CBP-1018, other than adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma, prostate cancer not requiring treatment, ductal carcinoma in situ of the breast, or < T1 urothelial carcinoma.

• Active central nervous system (CNS) metastases. Previously diagnosed CNS metastases are eligible if have been treated and recovered from the acute effects of radiation therapy or surgery prior to the first dose of CBP-1018, have discontinued corticosteroid treatment for CNS metastases for at least 4 weeks and are neurologically stable.

• Major surgery, systemic anticancer therapy (chemotherapy, targeted therapy, immunotherapy, endocrine therapy, biotherapy) or participation in other therapeutic studies within 4 weeks prior to the first dose of CBP-1018.

• Radiotherapy administrated within 21 days prior to the first dose of CBP-1018, or localized palliative radiotherapy administered within 7 days prior to the first dose of CBP-1018.

• Any toxicities attributed to prior anti-cancer therapy, other than alopecia and fatigue, that have not resolved to Grade 1 (NCI CTCAE 5.0) or baseline prior to the first dose of CBP-1018.

• Poorly controlled concurrent diseases as diabetes, hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure > 100 mmHg), etc.

• History of any of the following cardiovascular conditions within 12 months of enrollment: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery by-pass graft surgery, symptomatic peripheral vascular disease, class III or IV congestive heart failure, as defined by the New York Heart Association.

• History of clinically significant lung diseases as interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis, or suspected to have these diseases by imaging at screening period.

• Active bleeding disorder or other history of grade = 3 hemorrhage within 4 weeks prior to the first dose of CBP-1018.

• Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose anticoagulants for maintenance of patency of central venous access device or prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin is allowed.

• History of deep vein thrombosis or pulmonary embolism within 6 months prior to the first dose of CBP-1018.

• Active infection requiring intravenous (IV) antibiotics within 1 weeks prior to the first dose of CBP-1018.

• Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).

• Positive Hepatitis B Surface Antigen (HepBsAg) (indicative of chronic Hepatitis B), positive Hepatitis total core antibody with negative HepBsAg (suggestive of occult hepatitis B) or detectable Hepatitis C virus Ribonucleic acid (RNA) by PCR (Hepatitis C Antibody test for screening, followed by PCR for Hepatitis C virus RNA if HepCAb is positive).

• Live-virus vaccination within 30 days prior to the first dose of CBP-1018. Seasonal influenza vaccines that do not contain live virus are allowed.

• Current or anticipated need for treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers.

• History or current evidence of any other condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the Investigator.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• CBP-1018
CBP-1018 for injection, IV infusion

Locations

Country	Name	City	State
China	Sun Yat-Sen memorial hospital, Sun Yat-Sen University	Guangzhou	Guangdong
China	Tianjin Medical University Cancer Institute and Hospital	Tianjin	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Coherent Biopharma (Suzhou) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Neuroendocrine or small cell transformation-associated markers of mCRPC	Neuroendocrine or small cell transformation-associated markers of mCRPC	12 months
Other	Potential metabolites of CBP-1018	Potential metabolites of CBP-1018 in human plasma, urine, feces, if appropriate.	12 months
Other	Biomarkers	Biomarkers in tumor tissues with relationships of CBP-1018 efficacy/safety including,but not limited to, FOLR1	12 months
Other	Biomarkers	Biomarkers in tumor tissues with relationships of CBP-1018 efficacy/safety including,but not limited to,PSMA	12 months
Primary	Incidence and severity of Adverse Events (AEs) in Part A	Incidence of dose limiting toxicity (DLTs), treatment-emergent adverse events (TEAE), treatment-related adverse events, serious adverse events (SAEs) and clinically significant changes in vital signs, physical examinations, electrocardiogram (ECGs), and clinical laboratory tests per the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE 5.0).	12 months
Primary	MTD of CBP-1018 in Part A	maximum tolerated dose(MTD)	12 months
Primary	Recommended Phase 2 dose (RP2D) of CBP-1018 in Part A	The recommended Phase 2 dose (RP2D) is defined as the dose level chosen by the sponsor (in consultation with the investigators) based on safety,tolerability, efficacy, PK data collected during the dose escalation study of CBP-1018.	12 months
Primary	ORR in Part B	ORR(Objective response rate) per RECIST 1.1 ,PCWG3 (only for bone lesions of prostate cancer)	enrollment to end of treatment up to 3 years
Secondary	Maximum serum concentration (Cmax)	Maximum serum concentration (Cmax) of CBP-1018 will be investigated.	12 months
Secondary	Time to maximum serum concentration (Tmax) of CBP-1018	Tmax of CBP-1018 will be investigated.	12 months
Secondary	Elimination half-life (T1/2) of CBP-1018	T1/2 of CBP-1018 will be investigated.	12 months
Secondary	AUC0-t of CBP-1018	AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration	12 months
Secondary	Clearance (CL) in the serum of CBP-1018 per unit of time	CL in the serum of CBP-1018 per unit of time will be investigated	12 months
Secondary	ORR in Part A	ORR(Objective response rate) per RECIST 1.1,PCWG3 (only for bone lesions of prostate cancer)	12 months
Secondary	Immunogenicity assessment	Anti-drug antibody(ADA) against CBP-1018 will be evaluated.	enrollment to end of treatment up to 3 years
Secondary	Duration of Response (DOR)	The DOR is evaluated by investigator according to RECIST 1.1.,PCWG3 (only for bone lesions of prostate cancer).	enrollment to end of treatment up to 3 years
Secondary	Progression-free survival rate (PFS)	The PFS is evaluated by investigator according to RECIST 1.1.,PCWG3 (only for bone lesions of prostate cancer).	enrollment to end of treatment up to 3 years
Secondary	Disease Control Rate(DCR)	The DCR is evaluated by investigator according to RECIST 1.1.,PCWG3 (only for bone lesions of prostate cancer).	enrollment to end of treatment up to 3 years